The case and the decision

A synthetic patient develops severe hyperammonaemia after protein feeding, against a background of protein aversion, renal tubular abnormalities, skeletal disease, pulmonary alveolar proteinosis and inflammatory blood findings. Key biochemical specimens were collected after treatment had begun.

What both tools recognise

Both identify lysinuric protein intolerance as the unifying hypothesis. The pattern spans several organs, so an explanation that accounts only for the acute ammonia result leaves important observations behind.

A genetically confirmed published LPI case had non-diagnostic urinary amino-acid and orotic-acid results. That establishes that such screening results do not invariably exclude the disorder; it does not establish how often that occurs or exactly how treatment changed this synthetic patient's specimen. [1]

How the explanations compare

OpenEvidence connects impaired dibasic amino-acid transport with reduced urea-cycle support and the protein-associated crisis. Its organ-by-organ explanation is educational and coherent. MontMedical uses distinct assessment, findings, limits and research sections, making it easier to inspect where the case observations end and interpretation begins.

Both notice the post-treatment collection issue. There is no defensible diagnostic advantage for MontMedical in this retained pair.

The teaching point

A normal or non-diagnostic result is interpreted in light of what was measured, when it was collected and which mechanism it can test. Neither tool should turn the possibility of a masked profile into a claim that non-diagnostic screens are routinely expected in every patient.

This pair helps define the standard we want: OpenEvidence's connected explanation, combined with explicit specimen timing and a clear account of what would confirm the leading hypothesis.